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Abstract: The Ebola virus (EBOV) has been recognised for nearly 40 years, with the most recent
EBOV outbreak being in West Africa, where it created a humanitarian crisis. Mortalities reported up
to 30 March 2016 totalled 11,307. However, up until now, EBOV drugs have been far from achieving
regulatory (FDA) approval. It is therefore essential to identify parent compounds that have the
potential to be developed into effective drugs. Studies on Ebola viral proteins have shown that some
can elicit an immunological response in mice, and these are now considered essential components
of a vaccine designed to protect against Ebola haemorrhagic fever. The current study focuses on
chemoinformatic approaches to identify virtual hits against Ebola viral proteins (VP35 and VP40),
including protein binding site prediction, drug-likeness, pharmacokinetic and pharmacodynamic
properties, metabolic site prediction, and molecular docking. Retrospective validation was performed
using a database of non-active compounds, and early enrichment of EBOV actives at different false
positive rates was calculated. Homology modelling and subsequent superimposition of binding site
residues on other strains of EBOV were carried out to check residual conformations, and hence to
confirm the efficacy of potential compounds. As a mechanism for artefactual inhibition of proteins
through non-specific compounds, virtual hits were assessed for their aggregator potential compared
with previously reported aggregators. These systematic studies have indicated that a few compounds
may be effective inhibitors of EBOV replication and therefore might have the potential to be developed
as anti-EBOV drugs after subsequent testing and validation in experiments in vivo.
Keywords: Ebola virus; phytochemicals; molecular docking; VP35; VP40; retrospective validation;
virtual screening
1. Introduction
Filoviridae, from the EBOV family, is a lipid-enveloped, negative-strand RNA virus that causes
Ebola haemorrhagic disease, characterised by fever and an ensuing bleeding diathesis that has high
mortality in both humans and non-human primates [1]. Although EBOV has been acknowledged for
nearly 40 years, the recent outbreak in West Africa has created an appalling situation in the region.
The outbreak started in March 2014 in the Republic of Guinea, and has continued to spread throughout
Sierra Leone and Liberia, where it is reported to be one of the largest outbreaks in history [2,3]. Mortality
rates range from 53% to as high as 90%, with a total of 7178 cases reported until 1 October 2014 [4,5].
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As of 30 March 2016, 28,610 suspected cases and 11,307 deaths have been reported in the most
affected countries of Guinea, Liberia, and Sierra Leone (Ebola Situation Report, March 2016) (Figure 1).
Although the virus is already on the verge of becoming a socioeconomic burden, no vaccine or
treatment has succeeded in controlling or treating the disease. The Ebola virus genus comprises
five species, each named after the location where it was first identified: Zaire (EBOV-Z), Sudan (EBOV-S),
Taï Forest (EBOV-T), Bundibugyo EBOV-B, and Reston (EBOV-R), with varying fatality rates [6]. A vaccine
against EBOV-Z has shown the potential of immune responses against surface glycoproteins and
nucleoproteins [7]. Several investigations into anti-Ebola drugs have been carried out, but no effective
drug has yet been approved by the FDA. Profectus Bioscience, Inc., a clinical-stage vaccine development
company, has recently developed VesiculoVax, a vectored Ebola virus vaccine, which is currently in
phase I clinical trials [8]. Several experimental drugs have also been tested against Ebola, including
a synthetic adenosine analogue (BCX4430) developed by BioCryst, which is reported to inhibit
filoviruses in humans [9]. This drug inhibits viral RNA polymerase activity by functioning as
a non-obligate RNA chain terminator. Tests against EBOV and the Marburg virus have been performed
in rodents, achieving promising results. However, tests have not yet been carried out in humans.
There have also been positive developments with ZMapp, which is a combination of two individual
monoclonal antibodies, MB-003 (Mapp) and ZMAb (Defyrus/PHAC), from a strain of the tobacco
plant. This treatment has been assessed in animals with a 43% success rate; however, as with others,
it has not yet been tested in humans [10]. One treatment regime, CMX001, was approved by the
FDA and administered to two Ebola patients in 2014. One patient, being critically ill, died, while the
other survived and was declared Ebola-free. However, in early 2015, trials ended as the manufacturer
withdrew support. Another treatment regime, T-705 (favipiravir), when tested on mammalian cells,
proved to be non-toxic [11]. In 2014, results of a clinical trial with this drug suggested a decrease in
the mortality of Ebola patients affected with lower levels of Ebola virus, while patients with higher
Ebola virus levels remained unaffected. Treatment with FGI-106, similar to T-705, had curative effects
on the Ebola virus when tested on animals. Ribavirin, a prodrug known for treating a variety of
viruses, was reported to have poor results against the Ebola virus [12]. Another drug, Lamivudine,
was tested on 15 Ebola patients and positive results were indicated. Thirteen patients survived and
maintained a virus-free state until at least the end of the course. Since being found effective against
Ebola in monkeys, TKM-Ebola treatment went into phase I clinical trials at the start of 2014. However,
these trials were partially suspended by the FDA due to adverse reactions with this drug, and in
March 2015, TKM-Ebola phase II clinical trials were stopped since statistical analysis indicated a lack
of progress. Triazavirin is currently being tested for its potential against the Ebola virus.
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An earlier search for a target-specific drug focused on the viral glycoprotein. It was observed
that the glycoprotein is the leading cause of vascular cell injuries, and also leads to direct structural
damage to endothelial cells, which in turn triggers a haemorrhagic diathesis [13]. The search has
now broadened to other proteins. Investigations on Ebola viral proteins VP24, VP30 and VP35 have
shown that an immunological response can be elicited in mice, and these proteins are now considered
as critical components of a vaccine designed to protect against Ebola haemorrhagic fever [7,14].
Sequence analysis of the Ebola virus has shown that the organization of the viral genome is similar to
that of Rhabdoviruses and Paramyxoviruses. The order of EBOV genes was also predicted as follows:
3′-NP-VP35-VP40-GP-VP30-VP24-L [15]. VP40, a 326 amino acid viral matrix protein, is the most
abundant protein in viral particles and is crucial to virus assembly and budding. The budding process
takes place at the plasma membrane after the assembly of VP40 and requires lipid raft microdomains.
VP40 is located under the viral bilayer and maintains the structural integrity of the particles [16,17].
It has also been observed that VP40 is essential for viral or host cell RNA metabolism during viral
replication [18,19]. We have identified VP40 assemblies in a filamentous structure and have shown
that disruption of these structures halts viral egress. Studies on the membrane binding and structural
properties of VP40 have revealed potential drug sites [18,20]. The crystal structure of VP40 shows that
it is an octamer and forms a pore-like structure that binds RNA. It is a monomeric structure, and both
N- and C-terminal domains are associated with the membrane. The RNA protein structure is stabilised
by 140 amino acid residues of VP40 (including residues Thr123, Phe125 and Arg134 of a fragment of
the N-terminal domain) and UGA (stop codon) of RNA, which is also a potential target for antiviral
drug design [14,18].
In the quest for a target site, considerable interest has also been shown in the multi-functional
VP35 protein. VP35 is crucial to viral replication and virulence. Its functions include inhibition of
IFN-α/β production and protein kinase R, suppression of RNA interference, and, most importantly,
being a cofactor for the viral polymerase domain (VP35 IID), responsible for most activities performed
by this protein [21–23]. The ability of VP35 to suppress RNA silencing enhances virus replication,
which makes VP35 another important target in drug design.
There are a few published studies that have identified other compounds against EBOV, as reviewed
by De Clercq (2015). Among them, some have highlighted the potential for the repurposing of
FDA-approved drugs on different Ebola strains [24–33]. Although these studies have shown promising
results, they were not exhaustive screens of all FDA drugs. It was also unclear whether these drugs
had biological activities when used in combination with therapies to overcome drug resistance, as the
virus is a highly variable species. Studies in silico have been published for Ebola VP35 and VP40,
and, very recently, a machine learning method that uses Bayesian and Support Vector Machine (SVM)
algorithms was proposed by Ekin et al. [25] for the identification of novel Ebola inhibitors from already
reported antiviral data. Over the past decade, there has been significant interest in the exploitation of
phytochemicals for pharmaceutical use, many of which have antiviral or anticancer activities; a few
studies have focused on the potential of phytochemicals as possible parental compounds for the
treatment of haemorrhagic fever [34,35]. Kolokoltsov et al. demonstrated that a cocktail of genistein
and tyrphostin AG1478, both of which are kinase inhibitors, forms a broad spectrum antiviral agent that
can be used for the treatment of both arenavirus and filovirus haemorrhagic fevers [36]. They established
that both genistein and tyrphostin individually inhibit the entry of these viruses into cells by interfering
with endocytosis and the activity of uncoating proteins. Such positive results confirm the view that the
exploration of phytochemicals for EBOV has potential.
A plethora of plant species have been found to produce novel antiviral agents, and a variety
of active phytochemicals have been isolated. Testing these compounds against specific viruses to
discover potential anti-viral compounds requires exhaustive effort and resources. However, virtual hits
can be determined using computational approaches such as molecular docking, virtual screening,
and machine learning. Moreover, the toxicity of these compounds can be predicted comparatively
quickly with state-of-the-art computational Quantity-Structure-Activity-Relationship (QSAR) analysis.
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The current study aimed to identify potential virtual hits from a wide range of credible
phytochemical databases using in silico approaches. To our knowledge, no one has attempted
to screen nearly 150,000 natural product compounds. This study used different chemoinformatic
approaches against Ebola VP35 and VP40, including protein binding site prediction, drug-likeness,
ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties, drug metabolism,
drug safety profiling, and molecular docking of a wide range of phytochemicals. In early drug discovery
processes through virtual screening, colloidal aggregation of small compounds is a primary source of
non-specific inhibition in an assay that can give false positive results [37]. Therefore, the best virtual
hits were further analysed to check for their aggregator potential compared with previously reported
aggregators. Retrospective validation through enrichment via a Receiver Operating Characteristics
(ROC) curve further helped us evaluate virtual hits and docking protocols. Comparative homology
modelling of other EBOV strains and structural alignments were performed to map binding site
residues of VP35 and VP40 in all Ebola strains under study. This systematic study has produced
promising findings that may help combat this deadly disease.
2. Results
2.1. Binding Site Analysis
A detailed investigation of binding pockets from X-ray determined crystal structures was
performed and evaluated through the Computed Atlas of Surface Topography of proteins (CASTp)
server. The recent dimeric structure of the VP40 protein reveals that blocking the N- or C-terminal
assembly inhibits EBOV assembly. Potential target residues include Thr123, His124, Phe125, Gly126,
Arg134, Asn136, Tyr171, and Phe172, of which Thr123, Phe125, and Arg134 are especially crucial for
docking studies as these residues interact with RNA [16,18].
NMR mapping and high-resolution X-ray crystal structure of VP35 revealed that small compounds
bind to the Ebola Interferon inhibitory domain (eIID), and also to VP35 domains that are essential
for the formation of the replication complex through molecular interactions with viral nucleoprotein.
There were two basic patches in IID: the first basic patch (FBP) and central basic patch (CBP). The former
is important for molecular interactions with the Ebola virus nucleoprotein and VP35 polymerase
cofactor function, whilst the latter has its role in VP35 dsRNA binding and inhibition of IFN [38]. It has
been shown that Ala221, Arg225, Gln241, Leu242, Lys248, Lys251, Pro293, Ile295, Ile297, Asp302 and
Phe328 are located near and inside the FBP groove. Approximately 20 residues from eIID make up the
binding pocket and are distributed evenly between the alpha helical and beta sheet subdomains.
2.2. In Silico Screening
To identify new natural anti-Ebola virtual hits, SBVS of 145,329 compounds and the application
of a series of filters led us to select 13 best hits that indicated high binding energies with promising
ADMET properties, as shown in Figure 2. These 13 virtual hits were further checked for colloidal
aggregator potential, using Aggregator Advisor, and seven virtual hits were finally selected. The schematic
representation of chronological virtual screening is shown in Figure 3. The natural product database,
containing 145,329 compounds, was built by combining libraries of Drug-like green compounds
(OTAVA chemicals), Phytochemical compounds (Pubchem), Natural products (Analyticon Discovery
and Selleck) and Flavonoids (Timtec and Indofine Chemical companies). Subsequently, filtering for
drug-likeness, Lipinski’s Ro5, Duplicates deletion, and one relevant pharmacokinetics parameters
(HIA) led us to consider 45,013 compounds globally. EBOV-Z VP35 and VP40 were used to perform
the SBVS procedure because of X-ray resolved structures present in PDB. A total of 45,013 compounds
were docked to the FBP groove of IID of EBOV-Z VP35 and the RNA-interacting region of EBOV-Z
VP40. The best Autodock Vina docking score for both proteins was considered and subjected to
further analysis. In particular, the Molecular Interaction Field (MIF) strategy-based rescoring function,
DrugScore eXtended, was employed. In order to set an energy cut-off so as to select the best virtual
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hits, the same Autodock Vina protocol was carried out for the 10 active compounds that were
determined experimentally to inhibit EBOV-Z VP35 by Brown et al. i.e., GA017 (PDB ID: 4IBB),
GA246 (PBD ID: 4IBC), VPL27 (PDB ID: 4IBD), VPL29 (PDB ID: 4IBE), VPL42 (PDB ID: 4IBF),
VPL48 (PDB ID: 4IBG), VPL51 (PDB ID: 4IBH, Unreleased PDB structure, therefore not included
in docking procedure), VPL57 (PDB ID: 4IBI), VPL58 (PDB ID: 4IBJ) and VPL60 (PDB ID: 4IBK).
For EBOV-Z VP40, an energy cut-off (−6.0 kcal/mol) was set because there was no ligand-bound VP40
structure present in PDB (Table S1).
Based on virtual hits binding energies, we decided to select the binding energy cutoff value
on both proteins. Particularly, based on Autodock Vina docking score (∆G), 451 compounds with
binding energies lower than −6.8 kcal/mol for EBOV-Z VP35 and 874 compounds with binding
energies lower than −6.00 kcal/mol for EBOV-Z VP40 were selected. These virtual hits were filtered in
terms of their DSX free energies of binding. Cut-off values lower than −95.82 kcal/mol for EBOV-Z
VP35 and lower than −91.25 kcal/mol for EBOV-Z VP40 led us to consider 296 and 453 compounds,
respectively. In order to further screen these 749 compounds, protein complexes were visually inspected
and 91 compounds were finally selected with promising high binding energies against both EBOV-Z
VP35 and VP40. These virtual hits were screened through extensive ADMET analyses and carefully
analysed for molecular interactions with binding site residues.
Int. J. Mol. Sci. 2016, 17, 1748 5 of 31 
 
10 active compounds that were determined experimentally to inhibit EBOV-Z VP35 by Brown et al. 
i.e., GA017 (PDB ID: 4IBB), GA246 (PBD ID: 4IBC), VPL27 (PDB ID: 4IBD), VPL29 (PDB ID: 4IBE), 
VPL42 (PDB ID: 4IBF), VPL48 (PDB ID: 4IBG), VPL51 (PDB ID: 4IBH, Unreleased PDB structure, 
therefore not included in docking procedure), VPL57 (PDB ID: 4IBI), VPL58 (PDB ID: 4IBJ) and 
VPL60 (PDB ID: 4IBK). For EBOV-Z VP40, an energy cut-off (−6.0 kcal/mol) was set because there 
was no ligand-bound VP40 structure present in PDB (Table S1). 
Based on virtual hits binding energies, we decided to select the binding energy cutoff value on 
both proteins. Particularly, based on Autodock Vina docking score (ΔG), 451 compounds with 
binding energies lower than −6.8 kcal/mol for EBOV-Z VP35 and 874 compounds with binding 
energies lower than −6.00 kcal/mol for EBOV-Z VP40 were selected. These virtual hits were filtered 
in terms of their DSX free energies of binding. Cut-off values lower than −95.82 kcal/mol for EBOV-Z 
VP35 and lower than −91.25 kcal/mol for EBOV-Z VP40 led us to consider 296 and 453 compounds, 
respectively. In order to further screen these 749 compounds, protein complexes were visually 
inspected and 91 compounds were finally selected with promising high binding energies against 
both EBO -Z VP35 and VP40. These virtual hits were screened through extensive ADMET analyses 
and carefully analysed for molecular interactions with binding site residues. 
 
Figure 2. Chemical structures of virtual hits are represented in 2D format. Figure 2. Chemical structures of virtual hits are represented in 2D format.
Int. J. Mol. Sci. 2016, 17, 1748 6 of 31
Int. J. Mol. Sci. 2016, 17, 1748 6 of 31 
 
 
Figure 3. Schematic workflow summarising the screening of Ebola virus (EBOV) inhibitors through 
a series of steps. 
2.3. Prediction of Pharmacokinetic Properties and Toxicity Assessment 
Pharmacokinetic properties (PK) and toxicity depend on the molecular descriptors of the 
compound. The Molinspiration online server was used to check the phytochemicals as drug 
candidates based on Lipinski′s filter (log p ≤ 5, molecular weight ≤ 500, hydrogen bond acceptors ≤ 
10, hydrogen bond donors ≤ 5). The bioavailability of these compounds was also determined by 
total polar surface area (TPSA) analysis, as this has been reported to correlate with excellent human 
intestinal absorption (HIA) and Caco-2 cell permeability. According to Veber′s rule for good oral 
bioavailability, the number of rotatable bonds must be no more than 10 while TPSA values must be 
≤140 Å. %ABS were estimated from the predicted TPSA values. It has been reported that passively 
absorbed molecules with a TPSA greater than 140 Å will have low oral bioavailability. According to 
the standards mentioned above, estimated percentages of absorption for common compounds 
ranged from 54.12% to 88.53%. In silico predictions of PK properties such as absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) are valuable tools to determine the likelihood of 
success of compounds for potential human therapeutic use [39]. The ADMET properties of 91 
common compounds of EBOV-Z VP35 and VP40 proteins were analysed using admetSAR 
(Available online: http://www.admetexp.org). It is essential for a parental compound to have an 
impressive ADMET profile. The BBB [40], HIA [41], aqueous solubility [42], Caco-2 cell permeability, 
CYP 450 inhibition [43], and AMES toxicity were calculated for 91 compounds and 13 virtual hits 
were able to pass these series of ADMET filters, as summarised in Table 1. 
 
Figure 3. Schematic workflow summarising the screening of Ebola virus (EBOV) inhibitors through
a series of steps.
. . re ictio of ar acoki etic ro erties a oxicity Assess ent
r c i etic r erties ( ) t icit e e t e lec l r escri t rs f t e
c . The Molinspiration online server was used to check the phytochemicals as drug candi ates
b sed on Lipinski’s filter (logp ≤ 5, molecular weight ≤ 500, hydrogen bond acceptors ≤ 10,
hydrogen bond donors ≤ 5). The bioavailability of these comp unds was also determined by total
p l r surface area (TPSA) analysis, as this has been reported to correlate with excellent
i t sti l s r ti ( I ) c - c ll r ilit . cc r i t r’s r l f r r l
i il ilit , t r f r t t l s st r t il l s st
140 . S ere sti te fr t r ict l s. It s r rt t t ssi l
s r l c l s it r t r t ill l r l i il ilit . cc r i t
t standards mentioned above, stimated percentages of absorption for common co pounds ranged
from 54.12% to 88.53%. In silico predictions of PK properties such as absorption, istri ti ,
t lis , excretion, and toxicity (ADMET) are valuable tools to determin the likelihood of success
of comp unds for potential human t erapeutic use [39]. The ADMET properties of 91 common
pounds of EBOV-Z VP35 and VP40 proteins were analysed using admetSAR (Available online:
http://www.admetex .org). It is essential for a parental comp und to have an i pressive ADMET
profile. The BBB [40], HIA [41], aqueous solubility [42], Caco-2 cell permeability, CYP 450 inhibition [43],
and AMES toxicity were c lculated for 91 ompounds and 13 virtual hits were able to pass these series
of ADMET filter , as ummarised in Table 1.
Int. J. Mol. Sci. 2016, 17, 1748 7 of 31
Table 1. Predicted ADMET assessment of 13 virtual hits.
ADMET Compd. 1 Compd. 2 Compd. 3 Compd. 4 Compd. 5 Compd. 6 Compd. 7 Compd. 8 Compd. 9 Compd. 10 Compd. 11 Compd. 12 Compd. 13
BBB + + + + + + + + + + + + +
HIA + + + + + + + + + + + + +
Caco-2 permeable − _ − − + + − − + + + − −
Solubility −3.16 −3.1 −3.25 −3.25 −5.24 −4.33 −4.38 −2.44 −2.53 −2.89 −2.62 −3.63 −2.53
P-gp
Substrate + − − + + − + − − − + − −
Inhibitor − − − − + − + − − − − − −
ROCT − − − − − − − − − + − −
CYP450 substrate
2C9 − − − − − − − − − − − − −
2D6 − − − − − − − − − − + − −
3A4 − − − − + − − − − + + +
CYP450 inhibitor
1A2 + + + + + − − − − − − −
2C9 − − − − + − − − − − − − −
2D6 − − − − − − − − − − − − −
2C19 + − − − + − − − − − − − −
3A4 − − + − + − − − − − + − −
CYP IP Low Low Low Low Low Low Low Low Low Low Low Low Low
AMES toxicity − − − − − − − − − − − − −
Carcinogens − − − − − − − − − − − − −
ADME, absorption distribution metabolism elimination; BBB, blood–brain barrier; HIA, human intestinal absorption; CYP450, cytochrome P450; CYP IP, CYP inhibitory promiscuity;
ROCT, renal organic cation transportation; +, present; −, not present.
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On the basis of the admetSAR prediction, all compounds were able to penetrate the BBB,
in addition to HIA, and were revealed as non-inhibitors for the P-gp inhibitor. None of the phytochemicals,
with the exception of compound 9, showed any inhibitory effects on the renal organic cation transporter
(ROCT). CYP enzymes, including various CYP450 substrates and inhibitors, play a fundamental
role in drug metabolism. The results showed that all compounds revealed low CYP inhibitory
promiscuity because these compounds were non-inhibitors for most of CYP450 enzymes, i.e., 2C9, 2D6,
2C19 and 3A4. Further drug metabolism analyses showed that all common compounds (Table 1) were
non-substrates for two CYP450 substrates (2C9, 2D6). Moreover, toxicity analyses based on AMES test
data revealed that none of the compounds were toxic or carcinogenic.
Virtual hits were further filtered through a series of drug safety profiling parameters and checked
for any undesirable moieties and substructures involved in potential toxicity through a series of
PAINS (Pan Assay Interference Compounds) filters. Compounds 8–10, 12 and 13 were not identified
by PAINS-1, 2 and 3, passed all oral bioavailability and drug safety filters, and were classified as
acceptable; compounds 1–7 and 11 were classed as intermediate and rejected. The latter compounds
had undesirable substructural moieties (low- and high-risk coumarines) and displayed issues with
drug safety profiling (Table 2).
2.4. Molecular Interaction with EBOV-Z VP35 and VP40
Protein complexes of EBOV-Z VP35 and VP40 with 13 hits were critically inspected by post-docking
analysis. All 13 compounds showed high binding affinities with EBOV-Z VP35 and VP40, ranging from
−9.2 to −7.0 kcal/mol and −7.2 to −6.4 kcal/mol with Autodock Vina, and ranged from −156.867
to −95.53 kcal/mol and −120.189 to −91.619 kcal/mol, respectively, with the DSX rescoring function,
as tabulated in Table 3. Ligplot analysis of both protein complexes inferred all-inclusive findings.
Many virtual hits, when docked with both proteins, adopted the same orientation for their single
bicyclic ring, highlighted by the curved line in Figure 4. These included compounds 1–3, 10, and 11
against VP35 and compounds 1–4 and 9 against VP40. All virtual hits also docked within the surface
groove of IID near the FBP surrounded by binding site residues, as determined by binding site
analysis, including Ile295, Gln241, Gln244, Pro293, Lys248, Leu249, Lys251, Ile297, Asp302 and Phe328.
Lys251 is a critical residue for VP35 polymerase cofactor function, as mutations of Lys251 led to the
loss of function [44]. With VP40, virtual hits were found interacting with three highly conserved RNA
interacting residues, i.e., Thr123, Phe125, and Arg134 as highlighted yellow surface along with other
core residues. Molecular docking simulations identified those important virtual hits that participated
in hydrogen and hydrophobic interactions with many key residues of both proteins. In complexes with
EBOV-Z VP35, compounds 3, 6–8 and 10 showed at least one or more hydrogen bonds with O and
N atoms of Gln241 and His296, sharing an H-bond distance between 2.93 to 3.27 Å (Figure 5C,F–H,J,
Table 3). Whilst in EBOV-Z VP40, All compounds except 1, 3, 6 and 9 were involved in at least
one or up to six H-bonds, having molecular distances between 2.7 and 3.29 Å (Figure 6B,D,E,G,H,J–M,
Table 3). H-bond analysis of EBOV-Z VP40 complexes showed that the OG1 atoms of Thr123 and
Thr173, and N atoms of Phe172 and His124, actively participated in H-bonds with many compounds.
Most interestingly, compounds 8 and 12 contributed to a network of 6 and 5 H-bonds with important
binding site residues. Besides H-bonds, a large number of hydrophobic interactions were present with
the residues surrounding the IID of VP35 and RNA interacting site of VP40, as represented in Figures 5
and 6. The 2D analysis further revealed that Ile295, Gln244, Lys248, Pro304, Phe328, Ile297 of VP35 and
Tyr171, Phe172, Thr173, His124, Phe123 of VP40 could form a network of hydrophobic interactions.
Consequently, this contributed to the binding energies of docked compounds as these interactions
mediated the firm binding of compounds to the binding site of the respective protein, inhibiting its
function. Table 3 also reports binding energies with corresponding DSX-scores. The rescored binding
energies reported by DSX forms the total score, including possible torsional and intramolecular
interactions. Along with Per Contact Score (PCS), the score is divided by the total number of atomic
interactions that show any contribution to obtain the final score within 6 Å.
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Table 2. Screening of 13 virtual hits from series of filters being applied.
Virtual
Hits
Oral Bioavailability
ADMET
Drug Safety Profiling
Filtered
State
Undesirable
Structuresmioties
Aggregator Advisor
Drug
Likeness
Lipinski’s
Ro5
Veber
Rule
Egan
Rule
GSK 4/400
Rule
Pfizer 3/75
Rule
Lilly MedChem
Rules Aggregator Likelihood Similar with
1
√ √ √ √ √ √ × √ Rejected High_risk
coumarines
Reported as an aggregator
Logp: 1.6 Tc: 97%
2
√ √ √ √ √ √ √ √
Intermediate Low_riskcoumarines Non-aggregator Logp: 2.0
3
√ √ √ √ √ √ × √ Rejected High_risk
coumarines
Reported as an aggregator
Logp: 2.0 Tc: 93%
4
√ √ √ √ √ √ √ × Intermediate Low_risk
coumarines
Reported as an aggregator
Logp: 3.2 Tc: 76%
5
√ √ √ √ √ √ × √ Intermediate Low_riskcoumarines
Not similar to any known
aggregator in in-house
database High Logp: 5.2
6
√ √ √ √ √ √ × × Intermediate Low_risk
coumarines
Reported as an aggregator
Logp: 4.0 Tc: 75%
7
√ √ √ √ √ √ √ × Rejected High_risk epoxide Non-aggregatorLogp: 2.8
8
√ √ √ √ √ √ √ √
Accepted No Non-aggregatorLogp: 0.4
9
√ √ √ √ √ √ √ √
Accepted No Non-aggregatorLogp: 2.6
10
√ √ √ √ √ √ √ √
Accepted No Non-aggregatorLogp: 1.1
11
√ √ √ √ √ √ × √ Rejected
Frequent_hitter
dopamine; Low_risk
benzodioxolane
Non-aggregator
Logp: 2.3
12
√ √ √ √ √ √ √ √
Accepted No Non-aggregatorLogp: 2.8
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Table 2. Cont.
Virtual
Hits
Oral Bioavailability
ADMET
Drug Safety Profiling
Filtered
State
Undesirable
Structuresmioties
Aggregator Advisor
Drug
Likeness
Lipinski’s
Ro5
Veber
Rule
Egan
Rule
GSK 4/400
Rule
Pfizer 3/75
Rule
Lilly MedChem
Rules Aggregator Likelihood Similar with
13
√ √ √ √ √ √ √ √
Accepted No
Reported as an aggregator
Logp: 0.2 Tc: 90%
Veber Rule; Bad or Good oral bioavailability rule (rotatable bonds≤ 10) and (TPSA≤ 140 Å or H-Bonds Donors + H-Bonds Acceptors≤ 12), Egan Rule; Bad or Good oral bioavailability
rule (0 ≥ TPSA ≤ 132) and (−1 ≥ logp ≤ 6), GSK4/400 rule; Bad or Good ADMET profile (logp ≤ 4) and (Molecular Weight ≤ 400), Pfizer 3/75 rule; Rule which narrates to compounds
with a logp (>3) and TPSA (<75) are almost 2.5 times more likely to be toxic as to be clean, Lilly MedChem Rules; a set of 275 rules to identify compounds that may interfere with
biological assays in terms of reactivity, interference with assay measurements, activities that damage proteins, and lack of druggability,
√
; Compounds fulfilled the criteria, ×;
couldn’t pass the criteria, Accepted; Compounds with no structural cautions, Intermediate; Compounds with low-risk structural cautions, Rejected; Compounds that include high-risk
structural cautions, Tc; Tonimoto coefficient.
Table 3. Molecular docking analysis.
Source-ID/Name/Formula
Autodock Vina (∆G) DSX Drugscore Molecular Interactions
EBOV-Z
VP35
(kcal/mol)
EBOV-Z
VP40
(kcal/mol)
EBOV-Z VP35 EBOV-Z VP40 EBOV-Z VP35 EBOV-Z VP40
Score
(kcal/mol) PCS
Score
(kcal/mol) PCS
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
Number of
Bonds
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
number of
Bonds
1
Timtec-ST45161107
2-Oxo-N-(2-{4-((2-oxo-2H-chromen-
3-yl)carbonyl)-1-piperazinyl}ethyl)-
2H-chromene-3-carboxamide
C26H23N3O6
−9.2 −7.1 −156.867 −0.265 −120.189 −0.255
Lys248,
Pro293,
Ile295,
Val245,
Phe328,
Ile297,
Asp302,
Pro304,
Gln244,
Tyr229,
Gly236,
His240,
Gln241,
Phe235
0 31 31
Gly126,
Thr123,
His124,
Thr173,
Phe174,
Ile82,
Phe172,
Tyr171,
Phe125,
Gly126
0 30 30
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Source-ID/Name/Formula
Autodock Vina (∆G) DSX Drugscore Molecular Interactions
EBOV-Z
VP35
(kcal/mol)
EBOV-Z
VP40
(kcal/mol)
EBOV-Z VP35 EBOV-Z VP40 EBOV-Z VP35 EBOV-Z VP40
Score
(kcal/mol) PCS
Score
(kcal/mol) PCS
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
Number of
Bonds
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
number of
Bonds
2
Otava-7118230235
2-Oxo-N-((4-oxo-3,4-dihydro-1-
phthalazinyl)methyl)-2H-chromene-
3-carboxamide C19H13N3O4
−8.6 −6.9 −133.08 −0.291 −95.698 −0.229
Ile303,
Pro304,
Asp302,
Gln244,
Val245,
Gln241,
Phe328,
Ile297,
Lys248,
Pro293,
Ile295
0 27 27
His124,
Phe125,
Thr123,
Tyr171,
Thr173,
Phe174,
Ile82,
Phe172
1 (3.18A)
Thr173 30 31
3
Timtec-ST50912611
N,N'-1,2-Ethanediylbis
(2-oxo-2H-chromene-3-carboxamide)
C22H16N2O6
−8.2 −7.2 −152.793 −0.317 −115.494 −0.247
Val245,
Pro293,
Ile303,
Ile295,
Lys248,
Gln241,
Pro304,
Gln244,
Asp302,
Phe328,
Ile297
1 (3.12)
His296 28 29
Phe174,
Ile82,
Thr173,
His124,
Thr123,
Phe125,
Arg134,
Tyr171,
Phe172
0 29 29
4
Timtec-ST50616170
N-(4-Methyl-2-oxo-2H-chromen-7-yl)-
4,5,6,7-tetrahydro-1,2-benzoxazole-
3-carboxamide C18H16N2O4
−8.3 −6.4 −111.212 −0.24 −93.831 −0.203
Val245,
Pro293,
Ile303,
Ile295,
Lys248,
Gln241,
Pro304,
Gln244,
Asp302,
Phe328,
Ile297,
Val294
0 29 29
Phe174,
Thr173,
His124,
Thr123,
Phe125,
Tyr171,
Phe172
1 (3.12A)
Thr173 28 29
5
Analyticon-NP-010155
7-{((1R,4aS,6R,8aR)-6-hydroxy-5,5,
8a-trimethyl-2-
methylidenedecahydronaphthalen-
1-yl)methoxy}- 2H-chromen-2-one
C24H30O4
−8 −6.3 −105.282 −0.25 −98.943 −0.232
Val294,
Ile295,
Pro304,
Gln241,
Gln244,
Lys248,
Val245,
Ala221,
Lys251,
Pro293
0 26 26
Thr123,
Thr173,
Phe125,
His124,
Gln170,
Gly126,
Tyr171
1 (2.85A)
Thr173 23 24
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Table 3. Cont.
Source-ID/Name/Formula
Autodock Vina (∆G) DSX Drugscore Molecular Interactions
EBOV-Z
VP35
(kcal/mol)
EBOV-Z
VP40
(kcal/mol)
EBOV-Z VP35 EBOV-Z VP40 EBOV-Z VP35 EBOV-Z VP40
Score
(kcal/mol) PCS
Score
(kcal/mol) PCS
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
Number of
Bonds
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
number of
Bonds
6
Otava-0115540195
N-(1-Naphthyl)-2-oxo-2H-chromene-
3-carboxamide C20H13NO3
−8 −6.9 −124.21 −0.269 −91.619 −0.283
Ile295,
Ile297,
Asp302,
Phe328,
Phe235,
Tyr229,
Gly236,
Pro304,
His240,
Gln241,
Pro293,
Val294,
Lys248,
Val245,
Gln244
1 (3.11)
Gln241 28 28
Phe125,
Arg134,
His124,
Thr123,
Phe172,
Thr173,
Tyr171
0 20 20
7
Analyticon-NP-019744
Kihadarnin A
C26H30O9
−7.8 −7.3 −102.276 −0.198 −91.924 −0.213
Gln244,
Lys248,
Ile295,
Pro293,
Leu249,
Val294,
Val245,
His296
1 (2.93)
His296 34 34
Phe125,
Arg134,
His124,
Thr123,
Phe172,
Tyr171
1 (3.27)
Arg134
1 (3.13)
Phe172
21 23
8
Analyticon-NP-005474
2-(4-Hydroxyphenyl)-4-oxo-3,4-
dihydro-2H-chromen-7-yl β-
D-glucopyranoside
C21H22O9
−7.7 −7 −123.944 −0.253 −116.708 −0.23
Val245,
Lys248,
Gln244,
Ile295,
Pro293,
Val294,
His296
3 (3.11A,
3.12, 3.22A)
His296
26 29
Phe172,
Thr123,
His124,
Gln170,
Gly126,
Phe125,
Tyr171,
Thr173
2 (3.01A,
3.03A)
Thr173
2 (3.19A,
2.70A)
Phe172
1 (2.97A)
Thr123 1
(3.16A)
His124
33 39
9
PubChem-CID17597017
6,8-Dimethyl-2-((8-methyl-1-oxa-
4,8-diazaspiro(4.5)dec-4-yl)
carbonyl)-4H-chromen-4-one
C20H24N2O4
−7.6 −6.7 −98.897 −0.258 −91.398 −0.213
Pro293,
Ile295,
Phe328,
Pro304,
Gln244,
Val245,
Lys248,
Val294
0 19 19
Phe172,
Thr123,
Phe125,
Tyr171,
Thr173
0 19 19
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Table 3. Cont.
Source-ID/Name/Formula
Autodock Vina (∆G) DSX Drugscore Molecular Interactions
EBOV-Z
VP35
(kcal/mol)
EBOV-Z
VP40
(kcal/mol)
EBOV-Z VP35 EBOV-Z VP40 EBOV-Z VP35 EBOV-Z VP40
Score
(kcal/mol) PCS
Score
(kcal/mol) PCS
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
Number of
Bonds
Binding
Site
Interacting
Residues
No. of
H-Bond
Interactions
No. of
Hydrophobic
Bonds
Interactions
Total
number of
Bonds
10
Analyticon-NP-000375
Lactupicrin
C23H22O7
−7.3 −7.5 −95.53 −0.214 −116.548 −0.217
Val 294,
Pro 293,
Gln244,
Lys248,
Val245,
Ile295,
Val294
1 (3.27)
His296 29 30
Phe172,
Thr123,
His124,
Gln170,
Gly126,
Phe125,
Tyr171
1 (3.10)
Thr123
1 (3.24)
Phe172
33 35
11
Analyticon_NP-014205
Parfumine
C20H19NO5
−7.3 −6.9 −111.517 −0.281 −95.502 −0.246
Phe328,
Val294,
Gln244,
Val245,
Lys248,
Ile295,
Pro293
0 24 24
Phe172,
Thr123,
His124,
Phe174,
Tyr171,
Thr173
1 (3.00)
Thr123
1 (3.21)
Phe172
21 23
12
Analyticon-NP-014522
(2R,2′R,4a′S,6′S,7′R,8a′S)-4,6′,7′
-Trihydroxy-2′,5′,5′,8a′-tetramethyl-
3′,4′,4a′,5′,6′,7,7′,8,8′,8a′-decahydro-
2′H-spiro(furo(2,3-e)isoindole-2,1′-
naphthalen)-6(3H)-one
C23H31NO5
−7.2 −6.9 −97.222 −0.227 −96.182 −0.243
Phe328,
Val245,
Val294,
Gln244,
Val245,
Lys248,
Ile295,
Pro293
0 26 26
Phe172,
His124,
Thr123,
Asn136,
Arg134,
Tyr171,
Thr173
1 (2.89A)
Thr173 1
(3.08A)
Phe172 1
(3.29A)
His124
1 (3.11A)
Thr123 1
(3.12A)
Asn136
21 26
13
Analyticon_NP-003228
Isorutarin
C20H24O10
−7 −6.4 −105.752 −0.238 −91.824 −0.194
Val245,
Asp302,
Ile297,
Gln241,
Val294,
Gln244,
Val245,
Lys248,
Ile295,
Pro293
1 19 19
Ile82,
Phe172,
His124,
Tyr171,
Phe125,
Thr123,
Thr173,
1 (2.96A)
Tyr171 1
(3.13A)
Thr123
19 19
Post-docking analysis is representing Binding energies G (kcal/mol), Rescoring binding energies, Per Contact Score (PCS), molecular interactions with EBOV-Z VP35 and VP40 (In bold
are common compounds for both viral proteins.)
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EBOV-Z VP35 (A) and VP40 (B). Conserved interacting residues are displayed in red circles. 
Figure 4. Protein ligand analysis by ligplot. Ligplots showed the conserved binding modes (outlined by the orange lines) of virtual hits with respective targets:
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Figure 5. Molecular surface representation of EBOV-Z VP35 with respective ligands. (A–M) Molecular surface representation (in green) with respective ligands 
displayed in stick format (in magenta). Binding site residues are in pink. Alongside each 3D complex are schematic representations of the 2D interactions (with a cutoff 
distance of 4 Å) between each ligand and EBOV-Z VP35 amino acid residue using Ligplot analysis. Residues involved in hydrophobic contacts are black and 
demarcated by a spoked red arc, while those involved in hydrogen bonding are green, along with the values of the distances. Atoms are shown in white for carbon, 
red for oxygen, and blue for nitrogen. 
Figure 5. Molecular surface representation of EBOV-Z VP35 with respective ligands. (A–M) Molecular surface representation (in green) with respective ligands
displayed in stick format (in magenta). Binding site residues are in pink. Alongside each 3D complex are schematic representations of the 2D interactions (with a cutoff
distance of 4 Å) between each ligand and EBOV-Z VP35 amino acid residue using Ligplot analysis. Residues involved in hydrophobic contacts are black and
demarcated by a spoked red arc, while those involved in hydrogen bonding are green, along with the values of the distances. Atoms are shown in white for carbon,
red for oxygen, and blue for nitrogen.
Int. J. Mol. Sci. 2016, 17, 1748 16 of 31
Int. J. Mol. Sci. 2016, 17, 1748 16 of 31 
 
 
Figure 6. Molecular surface representation of EBOV-Z VP40 with respective ligands. (A–M) Molecular surface representation (in green) with respective ligands 
displayed in stick format (in magenta). Binding site residues are in pink. Residues Thr123, Phe125, and Arg134 form the catalytic triad in the active sites that interact 
with RNA are displayed in yellow. Alongside each 3D complex are schematic representations of the 2D interactions (with a cutoff distance of 4 Å) between each ligand 
and EBOV-Z VP40 amino acid residue using Ligplot analysis. Residues involved in hydrophobic contacts are black and demarcated by a spoked red arc, while 
those involved in hydrogen bonding are green, along with the values of the distances. Atoms are shown in black for carbon, red for oxygen, and blue for nitrogen. 
Figure 6. Molecular surface representation of EBOV-Z VP40 with respective ligands. (A–M) Molecular surface representation (in green) with respective ligands
displayed in stick format (in magenta). Binding site residues are in pink. Residues Thr123, Phe125, and Arg134 form the catalytic triad in the active sites that interact
with RNA are displayed in yellow. Alongside each 3D complex are schematic representations of the 2D interactions (with a cutoff distance of 4 Å) between each ligand
and EBOV-Z VP40 amino acid residue using Ligplot analysis. Residues involved in hydrophobic contacts are black and demarcated by a spoked red arc, while those
involved in hydrogen bonding are green, along with the values of the distances. Atoms are shown in black for carbon, red for oxygen, and blue for nitrogen.
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2.5. Alignments and Structural Studies
Multiple sequence alignments of the EBOV-Z VP35 and VP40 protein sequences (Figure 7A) across
five different strains showed extremely high conservation throughout the entire length of the sequences,
including 193 residues in VP35 and 217 residues in VP40; these residues are completely conserved
among all the Ebola strains examined. Residue conservation across the Ebola virus strains is suggestive
of the importance and necessity of these residues in Ebola virus functions. This inferred a strong
selection pressure to prevent any variation in sequence, and may also highlight important functional
domains and structural features. This is evident from sequence alignment, in that the structurally
important residues present in the binding site were conserved in EBOV VP35 and VP40 of all Ebola
strains under investigation (Figure 7A). To determine the probable conserved binding site residues of
Ebola strains, an effort was made to map the binding site residues of all strains by superimposing their
3D structures. In this regard, homology modelling of EBOV VP35 (Sudan, Tai Forest and Bundibugyo)
and VP40 (Tai Forest, Bundibugyo and Reston) was performed. The homology-based search inferred that
the 3D coordinate crystal structure of the Reston Ebola virus RNA binding domain (PDB ID: 3KS4),
in addition to the crystal structure of the Sudan Ebola virus matrix protein VP40 (PDB ID: 3TCQ),
were the best hits based on query coverage, E-value, and identity; therefore, this was considered
to be the best template for homology modelling (Table 4). For both 3D structures, chain A at 3.0 Å
was used as a coordinate structure for homology modelling. As presented in Figure 7B, all binding
residues of VP35 in EBOV-S, EBOV-B, EBOV-R, and EBOV-T exhibited close structural similarities with
EBOV-Z respective residues by sharing an RMSD (root mean square deviation) value of 0.2–1.5 Å,
respectively. Similarly, in VP40, the superimposition of highly conserved RNA interacting residues
Thr123, Phe125, and Asn134 of EBOV-S, EBOV-B, EBOV-R, and EBOV-T resulted in an RMSD value
between 1.5 and 2.71 Å. The data revealed that the binding site residues of VP35 and VP40 of EBOV-S,
EBOV-B, EBOV-R, and EBOV-T maintained a similar conformational pattern to that of EBOV-Z by
sharing a common 3D structural arrangement (Figure 7B). To validate the biological significance
of the binding site residues of all Ebola strains, 3D structural comparisons of VP35 and VP40 for
EBOV-Z, EBOV-S, EBOV-B, EBOV-R and EBOV-T were performed (Figure 7C,D). These structures were
superimposed to compare the conformations of conserved binding site residues structurally, in order
to further narrow down the interaction crosstalk against docked complexes of EBOV-Z VP35 and VP40.
To further increase the scope of underlying study, reported mutations were traced out in both proteins
from the data published by Gire et al., of EBOLA surveillance. The study reported that Arg37, Ser41,
Val170, Thr191, Asn254, Ile258, Ser272 and Ala9, Val20, Leu75, Ala77, Ile94, Pro131, Pro164, Val166,
Thr183, Thr197, Ser278, Ile324 in EBOV-Z VP35 and VP40 carried unique bases in 2014 outbreak strains,
while VP35-Val87, Ala156, Asp204, VP40-Ile94, and Thr65 were polymorphic across the 2014 outbreak
isolates [45]. The presented data clearly accords with the conservation of binding site residues across
all strains of EBOV.
Table 4. Homology modelling of EBOV different strains.
Target Proteins Ebola Strains Template PDB ID Query Cover E-Value Maximum Identity
VP40
EBOV-T 3TCQ.A 100% 0 76%
EBOV-R 3TCQ.A 98% 0 79%
EBOV-B 3TCQ.A 86% 0 88%
VP35
EBOV-S 3KS4.A 51% 6.00 × 10−105 81%
EBOV-T 3KS4.A 49% 3.00× 10−102 82%
EBOV-B 3KS4.A 49% 2.00× 10−100 80%
PSI-BLAST aligned templates against Protein Data Bank (PDB) repository, of EBOV VP35 (Sudan, Tai Forest and
Bundibugyo) and VP40 (Tai Forest, Bundibugyo and Reston) with query coverage, E-value, and maximum identity.
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Figure 7. Structural analysis of different Ebola strains. (A) Multiple sequence alignment of viral protein 35 (VP35) and 40 (VP40) of Ebola Zaire, Reston, Côte d’Ivoire, Sudan 
and Bundibugyo along with their chain length. Residues are coloured according to default colouring scheme of clustalX. Important structural residues of binding sites of 
VP35 and VP40 among the five Ebola subtypes are highlighted with a black outline, and labelled by residue name, as indicated by an arrowhead. The red arrowhead 
indicates RNA interacting residues (Thr123, Phe125 and Arg134) of VP40, which are also conserved among all subtypes. Sequences of representative Ebola virus subtypes 
were retrieved from GenBank and aligned using ClustalW. The alignment was further hand curated using Jalview 2.7; (B) Structural comparisons of conserved binding 
site residues. Individual RMSD values of conserved binding site residues (VP35 in left, VP40 in right) of all Ebola strains are plotted against the corresponding residues of 
EBOV-Z. The RMSD analysis shows that binding site residues of EBOV-S, EBOV-R, EBOV-B and EBOV-T contain a close structural similarity with corresponding residues of 
EBOV-Z; Structural superimposition of VP35 (C) and VP40 (D) are displayed in the bottom. Amino acid side chains highlight the conserved binding site residues of VP35 and 
VP40 in all strains as EBOV-Z (tan), EBOV-S (plum), EBOV-T (green), EBOV-B (sky blue), EBOV-R (coral), top ligands (wire form) are docked in the binding site of EBOV-Z. 
Molecular surface of the EBOV-Z binding site is highlighted in brown. 
Figure 7. Structural analysis of different Ebola strains. (A) Multiple sequence alignment of viral protein 35 (VP35) and 40 (VP40) of Ebola Zaire, Reston, Côte d’Ivoire,
Sudan and Bundibugyo along with their chain length. Residues are coloured according to default colouring scheme of clustalX. Important structural residues of binding
sites of VP35 and VP40 among the five Ebola subtypes are highlighted with a black outline, and labelled by residue name, as indicated by an arrowhead. The red
arrowhead indicates RNA interacting residues (Thr123, Phe125 and Arg134) of VP40, which are also conserved among all subtypes. Sequences of representative
Ebola virus subtypes were retrieved from GenBank and aligned using ClustalW. The alignment was further hand curated using Jalview 2.7; (B) Structural comparisons
of conserved binding site residues. Individual RMSD values of conserved binding site residues (VP35 in left, VP40 in right) of all Ebola strains are plotted against the
corresponding residues of EBOV-Z. The RMSD analysis shows that binding site residues of EBOV-S, EBOV-R, EBOV-B and EBOV-T contain a close structural similarity
with corresponding residues of EBOV-Z; Structural superimposition of VP35 (C) and VP40 (D) are dis layed in the bottom. Amino acid side chains highlight the
cons rved binding site residues of VP35 and VP40 in all strains as EBOV-Z (tan), EBOV-S (plum), EBOV-T (green), EBOV-B (sky blue), EBOV-R (coral), top ligands
(wire form) are docked in the binding site of EBOV-Z. Molecular surface of the EBOV-Z binding site is highlighted in brown.
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2.6. Retrospective Evaluation Virtual Screening Method
Retrospective validation is usually considered a benchmark for the success of VS methods.
It enumerates the number of actives found with respect to the fraction of inactives. The NSCC.11
statistical package was employed to determine the ROC curve plotted between the true positive rate
(Sensitivity) and the false positive rate (1–specificity) and the areas under the ROC-curves (AUC)
were calculated for comparison. Conjointly, the enrichment factor (EF) was also calculated in terms
of the ratio of true positives in the hit list at a given percentage of the database. These parameters
provide a useful and practicable evaluation performance for determining the discriminatory power
of the VS protocol [46]. The value of AUC fluctuated between 0 and 1, where 1 represents a perfect
screen whilst 0.5 relates to a random screen. Figure 8 represents the overall profile of percentage of
ligands found at ordinate (true positives) and at abscissa (false positives) positions for EBOV-VP35
(Figure 8A) and VP40 (Figure 8B). The ROC curve signified the evolution of sensitivity as well as
specificity, and sensitivity as a function of (1–specificity).The percentage actives were also plotted
against percentage inactives at all possible detected thresholds. The data using the ROC curve indicated
a noticeable separation between the groups, with an AUC of 0.931 (Standard Error, 0.057) and a 95% CI
(confidence interval) of 0.67 to 0.98 for EBOV-VP35 while the sensitivity and specificity were 80.77% and
76.91%, respectively. On the other hand, EBOV-VP40 showed a sensitivity and specificity of 76.36% and
71.11%, respectively, with an AUC of 0.830 (Standard Error, 0.0519) and a 95% CI (confidence interval)
of 0.69 to 0.90. The enrichment formulation is also used to report the ratio of true positives (found on
the Y-axis in an ROC plot) to false positives (the X-axis in an ROC plot). The EF was calculated at
different false positive rates in the ranked database. Therefore the theoretical maximum EF for subset
levels of 1%, 5%, 10% and 20% were 100, 20, 10 and 5, respectively. For EBOV VP35, 14.2%, 57.14%,
78.57% and 100% of the known actives were found in the top 1%, 5%, 10% and 20% of the docked
ranked database, respectively, corresponding to EFs of 14.28, 10, 7.85 and 5. Corresponding EBOV
VP40 values were10.5%, 52.6%, 73.6% and 94.7% of VP40 virtual hits, producing EFs of 10.52, 10.52,
7.36 and 4.73, respectively (Figure 8A,B).
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2.7. Aggregator Advisor Screening
To determine whether a virtual hit is already known to aggregate, leading to non-specific
inhibition, Aggregator Advisor was employed on 13 virtual hits. The Aggregator Advisor works
in close collaboration with lipophilicity and similarity thresholds (Tonimoto coefficient, Tc). If the
calculated Logp was >3, five out of seven compounds with Tc values ≥95% of known aggregators
aggregated at relevant concentrations; 10 out of 19 compounds with Tc values between 94% and
90%, and three out of seven compounds with Tc values between 89% and 85% also aggregated.
Another three compounds within these ranges were weak aggregators and may aggregate at higher
concentrations. All 13 virtual hits were checked for aggregator potential, as presented earlier in Table 3.
In the default affinity range of 0.1–10 µM, Aggregator Advisor indicated that seven compounds
had not previously been reported as aggregators, or as having similarities to a known aggregator.
With Logp < 3Tc < 85%, compound 5 was predicted to be dissimilar to any known aggregator in the
database, but this molecule had a relatively high calculated Logp of 5.3, which was in the range
reported for many other aggregators, so appropriate controls need to be performed in vitro in order to
test for possible aggregation. Compounds 2–4 were similar to compounds that have previously been
reported as aggregators with similarities of 90%, 93% and 87% respectively [47].
2.8. Metabolic Sites Analysis
MetaPrint2D is a quick, productive, and precise predictor of metabolic sites and products of
metabolism in small compounds, using circular fingerprints and substrate/product proportions.
The atoms displayed in red, orange, green, and white represent the most favourable metabolic sites,
followed by medium, low, and very low, respectively. In this current study, MetaPrint2D predicted
that most of the virtual hits favoured metabolic sites, i.e., various methoxy, oxygen, and nitrogen
groups of virtual hits, followed by red, orange, and green groups (Figure 9). As Figure 9 shows for
compounds 1, 2 and 5, the most favoured and moderate metabolic sites were associated with oxygen
and methoxy groups.
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3. Discussion
Ebola VP35 plays a major role in viral assembly, as it acts as a viral assembly factor and also as
a crucial component of the viral RNA polymerase complex. It impedes the host immune response
by interfering with interferon (IFN) production. The dsRNA binding cluster, which is reported to be
centred on Arg312, is highly conserved and fundamental for EBOV virulence [48]. Inhibiting VP35
activity causes reduced viral amplification and lethality in infected mice [49]. The EBOV VP35 is thus
a vital drug target because of its multifunctional role in viral replication, the antagonising of host
immune responses, and its role as a cofactor for the viral polymerase complex [28].
Ebola viral protein VP40 is reported to be associated with the assembly budding process and
stability of the virus. It contains two short sequence motifs, i.e., PPXY and PTAP found at its N-terminus.
It is implicated in virus release via interaction with cellular factors [18]. The N-terminal domain of
VP40 is also involved in dimerization, whereas the C-terminal domain harbours membrane binding
motifs [50]. Inhibition of VP40 results in failure of viral particle formation. Interestingly, in the
absence of other proteins, VP40 continues to form virus-like particles when expressed in a human
cell [51]. Furthermore, VP40 forms associations with microtubules and actin that help in movement
and assembly [52]. Most importantly, it plays a crucial role in viral transcription by forming an RNA
binding octameric ring. Both Ebola targets were considered as having the potential for screening large
compound libraries in early drug discovery processes and several high-throughput studies have been
performed recently on drug repurposing. However, to avoid the risk of rapid development of drug
resistance, repurposed drugs must follow strict criteria because a few mutations can drastically alter
the biological properties of RNA viruses [24,26,27,30,53–56].
The development of Ebola drugs is still remote from having FDA approval. Despite all
experimental data, drugs that were thought could eliminate Ebola virus did not work. Production of an
effective drug, ZMapp, for instance, is costly and time-consuming, and it was not subjected to clinical
trials to check for its efficiency [10]. Lamivudine, being inexpensive, has been chosen as the best option
for further analysis. The success rate of two new drugs, GS-5734 and BCX-4413, has been reported
to be 100%. These drugs, however, have not as yet been tested in humans. Brincidofovir has a high
success rate and has been tested in 1000 humans against many viruses except Ebola. Information about
this drug’s effectiveness against Ebola is still lacking. Brincidofovir and T-705 have an advantage over
other drugs as they both may be administered in the form of tablets, making distribution easier and
thus increasing its potential effectiveness against Ebola virus. For these reasons, the T-705 trial has been
approved to be expanded to examine this drug’s efficacy in a larger population of Ebola-infected people.
The current systematic study attempts to identify anti-EBOV compounds of plant origin
that may be considered as parental compounds for antiviral drug development. Structure-based
virtual screening of 145,329 natural compounds against two EBOV proteins has assisted in robust
screenings for the novel, potent virtual hits. These (a) followed drug-likeness and Lipinski’s Ro5 as
important criteria for characterising novel hits by screening large chemical libraries. Compounds
violating more than one drug-like parameter may have issues with bioavailability and therefore were
eliminated from the study; (b) showed successful BBB and HIA since polar molecules are poor CNS
drugs, whereas moderately lipophilic compounds cross the BBB. Through the process of molecular
docking, the best possible orientations forming stable ligand-target protein complexes were achieved,
coupled with a Molecular Interaction Field (MIF) strategy based on rescoring function. Based on
the experimentally determined VP35 inhibitors by Brown et al., the binding energy cutoff was set
to select for possible dual virtual hits that could act on both EBOV proteins. By the application
of a combined binding energy cutoff, 749 hits remained, which were further reduced to 91 that
showed high binding affinity for both EBOV proteins. Recent crystallography analyses also recognised
identical ligands for different proteins [57]. The present study revealed a varying trend in docking
results obtained against both Ebola viral proteins (VP35 and VP40) of the Zaire strain. This was
conducted using Autodock Vina alongside the rescoring function of DSX-score to evaluate binding
energies. Based on a comparative assessment of scoring functions, as determined by Cheng et al.,
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(2009) DSX devised by Kelbe achieves better results regarding docking power [58]. Further, CSD-based
potentials yield better results compared to PDB-based potentials due to the availability of better
resolved small crystal structures and more comprehensive contact data for a specific set of atoms.
The structures of several compounds in complexes with VP35 and VP40 highlighted several H-bonds
and hydrophobic interactions between functional groups, and side chains of essential residues for
Ebola viral protein functions. High binding energies (−9.2 to −7.4 kcal/mol) were observed against
VP35, whereas the binding energy for VP40 ranged from −7.2 to −6.4 kcal/mol. The efficiency of
ligand–protein complex formation can be quantified by calculating the binding energy of the ligand and
its half-life. With an increase in the value of binding energy, the rate of dissociation slows. For weaker
interactions, the rate of dissociation is rapid [59]. This suggests that compounds with strong binding
energies take a longer time to dissociate and thus have a longer half-life. Strong interactions between
residues imply that binding with inhibitory compounds may be stable, leading to an inhibitory reaction.
Interestingly, binding orientations of top hits with interacting residues of VP35, as evident from this
investigation, was also demonstrated through co-crystallized structures of specific VP35 inhibitors [53]
(Figure S1). To predict the conformation of compounds on other Ebola strains, binding sites were
superimposed, providing a strong indication of multi-targeted behaviours of the virtual hits.
Interestingly, all top hits showed promising ADMET properties; the body can either metabolise
poor PK/PD candidates, might result in toxicity or be unable to cross membranes. Furthermore,
the cytochrome P450 analysis was carried out for its most crucial isoforms: CYP1A2, CYP2A6, CYP2C9,
CYP2C19, CYP2D6, CYP2E1 and CYP3A4. The cytochrome P450 superfamily plays vital role in
drug metabolism and excretion from the liver [48]. Inhibition of these isoforms encourages drug
interactions, due to which, a co-administered drug may fail to metabolise and can accumulate in the
body to toxic levels. The Log S or aqueous solubility of a drug affects its absorption and distribution.
Predicted solubilities of the virtual hits under study were within an acceptable range. Virtual hits
were further checked for the presence of any toxicophore through a PAINS filter, oral bioavailability
and drug safety profiling. According to Baell et al., PAINS moieties are compounds that appear as
frequent hitters (as promiscuous compounds) in a number of biochemical high throughput screens [60].
Consequently, such compounds should be removed to prevent possible toxicity during early stages
of drug development [61]. Limonin [62] and Neoglucobrassicin [63] were predicted as anti-Ebola
compounds but showed high-risk structural alerts, including (a) high-risk epoxides that form protein
adducts, thus potentially disturbing signal transduction cascades [64] and (b) high-risk quinones
that lead to the formation of reactive oxygen species (ROS) and cause severe oxidative stress [65].
Furthermore, quinone-like compounds comprise structures that are widely reported to yield false
positives or are inactive [60]. We, therefore, employed PAINS filters to analyse high-risk chemical
groups, with the result that 5/13 virtual hits did not encounter any PAINS moieties and were therefore
classed as acceptable.
Docking-based VS methods have been evaluated by exploring their ability to prioritize (i.e., rank)
known active compounds that have been seeded into a collection of inactive (either known or
presumed) compounds. In VS validation, success is defined as the ability to enrich some relatively
small fraction of best-scored ligands with respect to the proportion of seeded known actives. Here we
were interested in identifying a significantly larger fraction of true actives from a ranked database than
from a random selection of compounds. Enrichment by VS methods may have a significant impact [66].
Therefore, enrichments were reported at different FP rates in Figure 8A,B. Notably, for subsets of
10% and 20%, the proposed VS method produced best enrichment factors of 7.85 and 5.45 for EBOV
VP35, and 7.36 and 4.73, respectively, for EBOV VP40. Although early enrichment at 1% and 5%
was a bit lower for both targets, this might be due to the low number of compounds in the ranked
database. Eventually, the VS method showed the best enrichment at a 10% false positive rate. As every
active compound in the ranked database raises the curve one unit on the Y-axis, a steep slope at the
beginning of ROC thus indicates a successful early enrichment of actives amongst the uppermost
ranked compounds.
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A key challenge in target-based assays that have been specifically prominent in high throughput
VS is the occurrence of a high rate of false positive hits (up to 95%) in a screen. These hits
are likely non-specific compounds and are found because of assay artefacts such as aggregation.
When Gossypentin and Taxifolin were screened as active multitarget inhibitors, these compounds
were found to be 94% and 91%, respectively, similar to compounds that have been reported as
aggregators [47,67–70]. Being a predominant mechanism for artefactual inhibition of proteins through
non-specific interactions, several controls against this are now widely employed to screen for virtual
hits with previously reported aggregators [71]. Therefore, we carefully analysed our best virtual hits
for non-specific inhibition of aggregation in biochemical assays within the affinity range between 0.1
and 1.0 µM. Of the 13 virtual hits, six compounds showed similarities with reported aggregators by
logp values and the Tonimoto coefficient, when analysed through Aggregator Advisor.
In summary, modern computer-based approaches are now becoming an important part of early
drug discovery processes; consequently, this may result in the development of promising and efficient
antiviral strategies. The Ebola virus is a worldwide threat, being extremely virulent and highly
transmissible. For a drug to be successful against EBOV, it is important that it targets more than
one protein and also different subtypes of the Ebola virus. It is possible to target more than one subtype
if potential sites are conserved and do not affect the tertiary structure of the virus. We have analysed
sequence variations through multiple sequence alignments between different subtypes of Ebola,
where there was no substantial change in the secondary structure of the proteins, and the function or
virulence of the virus was conserved. Many of the compounds studied here have not been tested for
antiviral activities. We have highlighted dual virtual hits that have the potential to inhibit VP35 and
VP40 proteins of the Zaire Ebola strain. Moreover, these compounds can be utilised as multi-target
drugs against both viral proteins and other strains of the Ebola virus; Ebola Zaire, Sudan, Reston,
Bundibugyo and Côte d’Ivoire. Extensive ADMET, drug safety profiling, and metabolic site analyses of
virtual hits were carried out followed by PAINS filter and analysis of aggregator potential. Among the
accepted virtual hits, four compounds had neither aggregator potential nor PAINS filter activity.
Furthermore, retrospective validation via ROC curve confirmed our virtual screening workflow.
Overall, we have used a systematic strategy to combine all of the above structural findings with
available and modelled 3D structural information of Ebola VP35 and VP40 proteins. This study
therefore provides a platform for the pharmaceutical industry and drug design laboratories to test
virtual hits in vivo with the aim of developing successful drugs.
4. Materials and Methods
4.1. Dataset Preparation and Filtering Procedure
An exhaustive literature survey was performed for a collection of phytochemical libraries from
e-molecule databases and natural product chemical companies including: Drug-like green collection of
OTAVA chemicals (Kiev, Ukraine) (129,000), PubChem (Phytochemical compounds) (2845), Analyticon
Discovery (The natural product company, Potsdam, Germany) (4967), Timtec LLC (Newark, DE,
USA) (4553), Indofine Chemical company (The flavonoid company, Hillsborough Township, NJ,
USA) (3833), and Selleck natural product library (131). All information on natural compounds was
merged, thus obtaining an overall database of 145,329 natural compounds. These compounds included
a wide range of chemical classes including flavonoids, terpenoids, poluines, lignans, polyphenolics,
saponins, thiophenes, furyl compounds, alkaloids, coumarins, sulphides, polysaccharides, lectins,
small peptides, and others. Duplicated structures were removed to acquire new scaffolds through
InChlKey generated by Open babel [72]. Lipinski violations were calculated to check for oral
bioavailability and pharmacokinetic parameters for crossing the blood–brain barrier (BBB), low toxicity
with good solubility, and better human intestinal absorption (HIA). Compounds displaying these
criteria were selected for further study. For retrospective validation of the database, actives and
inactives against Ebola viral proteins, and decoys (compounds that are physicochemically similar to
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the active compounds apart from activity) were retrieved from PubChem and substance data were
downloaded [73]. The 2D files of structures were converted to MOL 3D structures using Open babel and
saved as .mol2 files [72]. Ligands were prepared by energy minimization using the Discovery Studio
program 3.5, as designed by Accelrys Inc. (San Diego, CA, USA). Crystal structures of ZEBOV VP40
(PDB ID: 1H2C) [18], with a resolution of 1.60, and ZEBOV VP35 (PDB ID: 4IBK) [40] (Brown et al.,
2014), with a resolution of 1.85, were obtained from the Protein Data Bank (Available online:
http://www.rcsb.org/pdb/) [74] and visualized on Discovery Studio 3.5. Co-crystallized water
molecules and small molecules were deleted to prepare the protein structure for multi-drug analysis.
Energy was minimized for the 1000 steepest descent steps at a root means square gradient of 0.02,
an update interval of 10 and with an AMBER ff12SB force field using UCSF Chimera 10.1 (Resource for
Biocomputing, Visualization and Informatics, University of California, San Francisco, CA, USA) [75].
4.2. Evaluation of Protein Binding Site
Potential drug sites for VP35 and VP40 have previously been identified and experimentally
confirmed in high-resolution crystals. Binding pockets of both proteins were examined from crystal
structures and were further evaluated using the Castp server (Computed Atlas of Surface Topography
of Proteins) (Available online: http://cast.engr.uic.edu), which locates all likely binding pockets.
The Castp algorithm critically determines the area and volume of each binding pocket and possible
cavities in a solvent accessible surface area [76].
4.3. Alignments and Homology Modelling
Multiple sequence alignment of VP35 and VP40 proteins of EBOV-Z, EBOV-R, EBOV-T, EBOV-S
and EBOV-B were created using MUSCLE, version 3.7 [77] and checked visually using Jalview 2.7 [75].
Crystal structures of VP35 and VP40 of all Ebola strains were not present in the protein data bank
repository. Therefore, to perform structural inferences, homology modelling was carried out for VP35
of EBOV-S, EBOV-T, and EBOV-B, and also for VP40 of EBOV-T, EBOV-B and EBOV-R. The protein
sequences of all viral proteins were taken from UniProt and searched via a position-specific iterative
BLAST (PSI-BLAST) [78] against the Protein Data Bank repository for a suitable template to generate
a 3D coordinate structure. Initial alignment between target and template was generated using the
ALIGN2D module. Then, the 3D coordinate structure of each viral protein was generated using
a restrained-based approach in MODELLER.v9.12 [79]. MODELLER infers distance and dihedral edge
restrictions on the target sequence from its alignment with 3-D template structures. These connections
are communicated as contingent likelihood thickness capacities. Spatial limitations are inferred
accordingly, with the stereochemistry authorized by CHARMM22 [80]. The power field terms were
consolidated into an objective function that was minimized by an improvement method during
model building. The predicted structures were refined using Procheck and structural alignment was
performed to check conformations of binding site residues of VP35 and VP40 between all Ebola strains
and respective RMSDs were calculated.
4.4. Structure-Based Virtual Screening
Autodock Vina, automated by Mcule drug discovery pipeline [81], was used to screen a natural
compounds database [82]. The Mcule docking engine was efficient and used a gradient optimization
method in its local optimization procedure. The gradient calculation algorithm effectively optimizes
a sense of direction from a single evaluation [83]. For structure-based virtual screening (SBVS), only the
EBOV-Z strain was considered because of the availability of well-resolved VP35 and VP40 crystal
structures in the Protein data bank repository. Each ligand was docked into the respective binding sites
of VP35 and VP40 of the EBOV-Z strain and was ranked as an energy function. The energy function
consisted of protein and ligand van der Waals’ and electrostatic interactions [84].
Grids were created from a grid generation panel and relaxed on the investigated binding side
of EBOV proteins. For VP35, a grid was made with dimensions of 30 Å × 30 Å × 30 Å, covering the
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IID First Batch Pocket (FBP); this was due to a previous investigation that found several small
compounds that were capable of binding VP35 IID with high affinity and specificity [53]. For VP40,
the interaction details of VP40 and RNA were taken from PDB and a 5 Å radius was selected for
docking with selected phytochemicals. The grid was constructed with dimensions necessary to contain
the RNA-interacting residues Thr123, Phe125 and Arg134. The protein complexes were analysed
through PyMol (The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrodinger, LLC) [85]
and UCSF Chimera 10.1 (Resource for Biocomputing, Visualization and Informatics, University of
California, San Francisco, CA, USA).
Further assessment of docking results was conducted employing DrugScore eXtended (DSX) [58]
which is a program that analyses the output of Autodock. DSX uses a knowledge-based scoring
function to evaluate binding energies of ligands bound to the delta-opioid binding site. The DSX-score
uses statistical pair potentials derived from the Cambridge Structural Database (CSD) and PDB [86].
Moreover, the solvent accessible surface potential (SAS-potential) that is associated with PDB potential
is introduced in a DSX-score that estimates desolvation effects. For the present work, CSD and
SAR potentials were used. Ligands with a larger, negative DSX-score have an estimated higher
binding energy.
4.5. Retrospective Virtual Screening Analysis
Retrospective validation of the capability of VS workflow to discriminate active compounds
from inactives is a most reliable method if the test library covers known actives and experimentally
verified inactive “True Decoy” compounds. Therefore, separation of actives in a pool of decoys was
imperative [87–89]. Nevertheless, there is a dearth of data available for confirmed inactive compounds
in public databases. We are grateful to Michael Lee for providing us with experimentally confirmed
actives and inactives of EBOV-VP35, while for EBOV-VP40, there was not a single study that confirmed
actives and inactives. Therefore, virtual hits against EBOV-Z VP40 were retrieved from the previously
published in-silico studies including current study. In this regard, DUD-e (DUD, available online:
http://dud.docking.org/) was employed to generate decoys for EBOV-Z VP40, and topological
dissimilarities between decoys and virtual hits were calculated using Daylight fingerprints
(Clustering package Irvine CA: Daylight Chemical Information System). Physical properties of virtual
hits were taken in account to generate decoys possessing similar properties. For the assessment of
virtual screening, a database was prepared consisting of experimentally confirmed 14 actives and
13 inactives against EBOV-VP35, whilst for EBOV-Z VP40, another database of 19 virtual hits and
50 decoys for each virtual hit were generated using DUD-e decoy generator, which were reduced to 44
on the basis of their molecular descriptors, leading to 836 decoys. To avoid biasing virtual screening
results, we also generated set of 359 decoys with similar physicochemical properties to known actives
of EBOV-VP35.These decoy sets were also seeded into corresponding databases. In such retrospective
calculations, docked actives and inactives were ranked by score, and Area under Curve (AUC)
was calculated by Receiver Operating Characteristics (ROC) curves and its 95% confidence interval
was calculated using NSCC.11 statistical software (NCSS 11 Statistical Software (2016). NCSS, LLC.
Kaysville, UT, USA) [90–93]. Early enrichment (EF) in true positives was computed at false positive
rates by the following formula:
EF =
a/n
A/N
(1)
where n = a total number of hits, a = the total number of actives in the n hits, N = total number of
compounds in the database, and A = the total number of actives in the database. Here we were more
interested in enrichment factors (EFx) at 1% (EF1), 5% (EF5), 10% (EF10) and 20% (EF20) false positive
rates (FP) in the ranked database of EBOV VP35 and VP40 as follows:
EFx =
TP
FPx
(2)
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All compounds for retrospective validation were transformed to 3-D format and minimised using
the procedure above.
4.6. Calculations of Pharmacokinetics and Toxicity Analysis
Physicochemical molecular descriptors and drug likeliness of phytochemicals were examined
using a Molinspiration server (Available online: http://www.molinspiration.com) based on the
Lipinski Rule of Five (LRo5) [91]. Compounds containing a violation according to the LRo5 were
removed from further analysis. The Molinspiration server predicts the most important properties
of compounds such as Logp, molecular weight, hydrogen bond acceptors and donors, and total
polar surface area (TPSA). The percentage of absorption (%ABS) was measured from the equation:
%ABS = 109 − (0.345 × TPSA) [92]. In order to identify possible adverse effects of virtual hits in
humans, the ADMET properties of the filtered compounds were inferred using a variety of tools.
These included: the OSIRIS property explorer (Available online: www.organic-chemistry.org/prog/
peo/), which is designed to highlight undesired effects, ADMET prediction suite by Advanced
Chemistry Development (ACD/Labs) Software for rapid profiling and screening of compounds
utilizing ADMET parameters, Molsoft (Available online: http://molsoft.com/mprop/) for calculation
of drug-likeness properties and AdmetSAR (Available online: http://lmmd.ecust.edu.cn:8000/) for
prediction of QSAR-based ADMET properties. This provides the user with a friendly interface for the
latest and most comprehensive, manually curated database for a diverse range of chemicals linked with
Absorption, Distribution, Metabolism, Excretion and Toxicity profiles [93]. Additionally, undesirable
substructure moieties and the drug safety profile of all filtered hits were projected [60,94].
4.7. Aggregator Advisor Prediction
Colloidal aggregation of organic molecules is the predominant mechanism that leads to
nonspecific inhibition [95,96] and sometimes activation [97,98]. This is a major source of false positive
results in early drug discovery processes through virtual screening [37]. In order to predict final
virtual hits that aggregate or may aggregate under biochemical assay conditions, Aggregator Advisor
(Available online: http://advisor.bkslab.org/), a tool to predict aggregating compounds and to advise
on the likelihood of aggregation, was employed. This is based on chemical similarities to known
aggregators (Tonimoto coefficient), and physical properties (e.g., Logp) [99].
4.8. Metabolic Site Prediction
MetaPrint2D (Available online: http://www-metaprint2d.ch.cam.ac.uk/) is a web-based tool
that predicts metabolic sites of compounds that undergo phase 1 metabolism based on their similarities
to known metabolic sites. MetaPrint2D predicts the metabolism of xenobiotics through data
mining and statistical analysis of known metabolic transformations, as reported in the scientific
literature [100]. This user-friendly software predicts the metabolic site by uploading a SMILES
(Simplified molecular-input line-entry system) format of compounds.
5. Conclusions
Involvement of computational tools has been widely used for drug development and discovery.
Viral target identification and investigation of host proteins involved in causing Ebola virus are
currently in focus. Lack of information regarding viral mechanism of action, binding sites and Ebola
drug targets poses a challenge in regard to the discovery of EBOV inhibitors. The design of effective
inhibitors with a potential to be used as anti-Ebola drugs can help to combat this disease.
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